Keywords
How to Cite
Abstract
Introduction: Due to their mechanism of action, beta blockers, despite their contraindications, are routinely used in those patients with Acute Myocardial Infarction. By blocking the effects of circulating catecholamines, it therefore reduces BP (Blood Pressure), myocardial contractility and heart rate, helping to improve myocardial perfusion. Objectives: To assess the safety and whether there is a reduction in mortality of beta-blocker therapy in cases of acute myocardial infarction. Method: For data collection, we used the PubMed platform, linked to the National Library of Medicine (NLM). We selected meta-analyses and randomized trials from the last 12 years. A total of 83 articles were found, of which 4 were selected, which correlated the benefits of using beta-blockers and the impact on the mortality of patients with Acute Myocardial Infarction. Results: The selected article observed lower mortality with doses of beta-blockers versus no therapy. As well as the use of higher doses, there is no change in the outcome. One article reports that in patients who will undergo percutaneous therapy, early use of intravenous beta-blockers is safe and protects against malignant arrhythmias, but the results on the impact on mortality are ambiguous. Two articles report that the use of beta-blockers in an acute form has a superior reduction when compared to the late blockade. Conclusion: We can observe that evidence from randomized clinical trials showed benefits and a significant reduction in mortality in the use of beta-blockers, in those patients with suspected or diagnosed acute myocardial infarction.